secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2023-10-31T23:59:59+00:00
Accession:  0000950170-23-056542
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 2.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam sells opt-in rights on Verve CVD programs to Lilly for $200M + $50M equity; up to $600M total
--------------------------------------------------------------------------------

- Beam receives $200M upfront and $50M equity (2,004,811 shares at $24.94, 15% premium to 30-day VWAP).
- Eligible for up to $350M in milestone payments; total potential deal consideration up to $600M.
- Deal expected to extend Beam's cash runway to second half of 2026.
- Lilly acquires opt-in rights to co-develop/co-commercialize Verve's PCSK9, ANGPTL3, and undisclosed liver target programs.
- Lilly agreed to 9-month lock-up on shares issued; transaction closed on October 27, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000095017023056542/0000950170-23-056542-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000095017023056542/beam-20231027.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-056542

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer